To test this idea, we focused on mechanistic target of rapamycin complex 2 (mTORC2), a core component of RTK signaling in a highly lethal brain tumor glioblastoma (GBM), especially in association with platelet-derived growth factor receptor (PDGFR) gene amplification as well as expression of the gain-of-function epidermal growth factor receptor (EGFR) mutation EGFRvIII [6, 26]. The gene discussed is EGFR; the disease is glioblastoma.